Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease

Neurology

Volumn 51, Issue 1 SUPPL., 1998, Pages

  Taylor, Palmer ^a  

^a San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DICHLORVOS; DONEPEZIL; DYFLOS; EDROPHONIUM; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; METRIFONATE; PHYSOSTIGMINE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL;

EID: 0031880242     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.1_suppl_1.s30     Document Type: Article

References (15)

1. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 1996:161-176.
2. Summers WK, Majovski V, Marsh, GM, Tachiki K, Kling A. Oral tetrahydroamino-acridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-1245.
3. Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994;34:281-320.
4. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototype acetylcholine binding protein. Science 1991;253:872-879.
5. Bourne Y, Taylor P, Marchot P. Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex. Cell 1995; 83:502-512.
6. Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993;90:9031-9034.
7. Geula C. Abnormalities in neural circuitry in Alzheimer's disease: the hippocampus and cortical cholinergic innervation. Neurology 1998;51(Suppl 1):S18-S29 (this issue).
8. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998:51(Suppl 1):S2-S17 (this issue).
9. McGehee DS, Heath MJS, Gelber S, Devoy P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in the CNS by presynaptic receptors. Science 1995;269:1692-1696.
10. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996;283:713-716.
11. Khan IM, Yaksh TL, Printz MP, Taylor P, Yaksh TL. Intrathecal nicotinic agonist-elicited release of excitatory amino acids as measured in vivo spinal microdialysis in rats. J Pharmacol Exp Ther 1996;278:97-206.
12. 3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different receptor subtypes from striatal dopamine release. Br J Pharmacol 1996;117:595-606.
13. Rouse ST, Thomas TM, Levy AI. Muscarinic acetylcholine receptor subtype, m2: diverse functional implications of differential synaptic localization. Life Sci 1997;60:1031-1038.
14. Adem A, Karlsson E. Muscarinic receptor subtype selective toxins. Life Sci 1997;60:1069-1076.
15. Segales J, Roumestand C, Zinn-Justin S, et al. Solution structure of a green mamba toxin that activates muscarinic acetylcholine receptors as studied by nuclear magnetic resonance and molecular modeling. Biochemistry 1995:34:1248-1260.